Evidence map›Paper›PMID 41771920›Full record

ArticleNature communications2026

Supramolecular coiled-coil peptide platform for site-specific antibody drug conjugate engineering.

Alina Ringaci, Ting-Yu Shih, Mark W Grinstaff

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alina RingaciDepartments of Chemistry and Biomedical Engineering, Boston University, Boston, MA, USA.
Ting-Yu ShihDepartments of Chemistry and Biomedical Engineering, Boston University, Boston, MA, USA.
Mark W GrinstaffDepartments of Chemistry and Biomedical Engineering, Boston University, Boston, MA, USA. mgrin@bu.edu.ORCID http://orcid.org/0000-0002-5453-3668

Funding

R21: A novel antibody-drug conjugate for treatment of squamous cell lung carcinomaR21CA273645 · NCI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI GRINSTAFF, MARK W. · 2022 to 2023
$420k
U.S. Department of Health & Human Services | National Institutes of Health (NIH) R21CA273645
6 · The paper itself

Abstract

Antibody conjugates play a central role across multiple healthcare sectors with a prime example being antibody-drug conjugates (ADCs). Although widely used lysine and hinge cysteine conjugation methods yield products, the lack of site-specificity and spatial control along with the highly heterogeneous composition are significant limitations. Herein, we describe a facile supramolecular assembly method based on heterodimer coiled-coil formation for site-specific antibody conjugation that perseveres antibody antigen binding sites for target engagement. The platform method affords uniform loading of diverse payloads including anti-cancer agents, polymers, enzymes, fluorophores, etc. under mild aqueous conditions. Further, the facile convergent approach capitalizes on the independent strengths and flexibility of protein expression and peptide chemistry culminating in a final self-assembly step. An ADC loaded with monomethyl auristatin E targeting ErbB2/Her2 positive tumors significantly reduces tumor volume in a human ovarian cancer xenograft model outperforming the antibody alone with validated performance against a best-in-class therapeutic.

Indexed as

ImmunoconjugatesOligopeptidesOvarian NeoplasmsPeptidesAnimalsAntineoplastic AgentsCell Line, TumorErb-b2 Receptor Tyrosine KinasesFemaleHumansMiceProtein EngineeringXenograft Model Antitumor AssaysAntineoplastic AgentsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoconjugatesmonomethyl auristatin EOligopeptidesPeptides

Identifiers

PMID41771920
PMCPMC13096297

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.